MichaelBHolmesMD

Cardiology • Cooperstown, NY

Chief of Cardiovascular Disease Bassett Healthcare Assistant Clinical Professor Columbia University

Join to view full profile

Dr. Holmes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Holmes' full profile

Already have an account?

Office
1 Atwell Rd
Suite 203
Cooperstown, NY 13326
Phone+1 518-377-8198

Fax+1 518-377-0620
Is this information wrong?

Summary

Dr. Michael Holmes is a cardiologist in Cooperstown New York and Little Falls New York. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice since 2001. He practices clinical and consultative cardiology . He is the chief of cardiovascular disease at Bassett Healthcare and an assistant clinical professor with Columbia University.

Education & Training

University of Vermont Medical CenterResidency, Internal Medicine, 1994 - 1997
Johns Hopkins University School of MedicineClass of 1994

Certifications & Licensure

NY State Medical License 2001 - 2024
VT State Medical License 1994 - 2002
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MEDENT EMR/EHR, Community Computer Service, Inc., 2011-2012
Heart/Stroke Recognition Program National Committee for Quality Assurance, 2011-2014

Publications & Presentations

PubMed

15 citations
Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab.
Michael B. Holmes, Samer S. Kabbani, Christopher M. Terrien, Matthew W. Watkins, Burton E. Sobel, David J. Schneider> ;Coronary Artery Disease. 2001 May 1
21 citations
Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin.
David J. Schneider, Patricia Q. Baumann, Michael B. Holmes, Douglas J. Taatjes, Burton E. Sobel> ;Thrombosis and Haemostasis. 2001 Feb 1
23 citations
Novel, Bedside, Tissue Factor–Dependent Clotting Assay Permits Improved Assessment of Combination Antithrombotic and Antiplatelet Therapy
Michael B. Holmes, David J. Schneider, Michael G. Hayes, Burton E. Sobel, Kenneth G. Mann> ;Circulation. 2000 Oct 24
12 citations
Abciximab-Associated Pseudothrombocytopenia
Michael B. Holmes, Samer S. Kabbani, Matthew W. Watkins, Robert W. Battle, David J. Schneider> ;Circulation. 2000 Feb 29
74 citations
Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy
Michael B. Holmes, Burton E. Sobel, Christopher P. Cannon, David J. Schneider> ;The American Journal of Cardiology. 2000 Feb 15
47 citations
Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects
Michael B. Holmes, Burton E. Sobel, David J. Schneider> ;The American Journal of Cardiology. 1999 Jul 15
50 citations
Differences between Activation Thresholds for Platelet P-Selectin and Glycoprotein IIb-IIIa Expression and Their Clinical Implications
Michael B. Holmes, Burton E. Sobel, Diantha B. Howard, David J. Schneider> ;Thrombosis Research. 1999 Jul 15
Join now to see all

Press Mentions

More Insights into AAA Genetics Spur New Questions on ScreeningSeptember 29th, 2020
25-Physician Cardiology Group to Join St. Peter's Health PartnersSeptember 16th, 2020
Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR HarmonyMarch 15th, 2019
Join now to see all